Ascendis Pharma A/S

Equities

ASND

US04351P1012

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 09:36:18 2024-07-15 am EDT 5-day change 1st Jan Change
138.8 USD +0.50% Intraday chart for Ascendis Pharma A/S +1.67% +9.63%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading MT
Ascendis Pharma, Pendopharm Sign Distribution Agreement for TransCon Parathyroid Hormone in Canada MT
Pendopharm Signs Exclusive Distribution Agreement with Ascendis Pharma A/S for TransCon PTH in Canada CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher Tuesday Trading MT
TD Cowen Upgrades Ascendis Pharma to Buy Rating With $175 Price Target MT
European Equities Traded in the US as American Depositary Receipts Trend Lower Friday But End Week Higher MT
Bank Stocks Help Nudge European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Tuesday Trading MT
Transcript : Ascendis Pharma A/S Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:00 AM
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading MT
Ascendis Pharma Reports 45% Clinical Response in TransCon IL-2 Phase 1/2 Trial MT
Ascendis Pharma A/S Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024 CI
European Equities Traded in US as American Depositary Receipts Rise Friday, Poised to End Week Lower MT
Stifel Initiates Ascendis Pharma at Buy Rating With $200 Price Target MT
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading MT
Morgan Stanley Adjusts Ascendis Pharma Price Target to $140 From $116, Maintains Equal Weight Rating MT
US Equity Markets Close Higher Tuesday as Producer Prices Rise MT
Sector Update: Health Care Stocks Rise in Late Afternoon Trading MT
Sector Update: Health Care MT
Ascendis Pharma Says US FDA Extends Review Period on Hypoparathyroidism Treatment; Shares Drop MT
Chart Ascendis Pharma A/S
More charts
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
126.6 EUR
Average target price
167.1 EUR
Spread / Average Target
+32.01%
Consensus
  1. Stock Market
  2. Equities
  3. ASND Stock
  4. News Ascendis Pharma A/S
  5. Morgan Stanley Adjusts Ascendis Pharma Price Target to $140 From $116, Maintains Equal Weight Rating